SynthesisCerebellum (London, England)2026
Low-Titer Anti-GAD Cerebellar Ataxia: Evidence That Diagnosis Should Extend Beyond Serum Antibody Levels - A Case Report and Systematic Review.
Synthesis in Cerebellum (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnti-glutamic acid decarboxylase (anti-GAD) antibodies are associated with cerebellar ataxia. Although high antibody titers are considered a key diagnostic feature, the significance of low titers remains uncertain. We describe a patient with low-titer anti-GAD cerebellar ataxia and systematically review the literature.
methodsWe report the case of a 38-year-old woman with autoimmune cerebellar ataxia associated with low-titer anti-GAD antibodies. A systematic review of PubMed/MEDLINE and SciELO identified published cases of cerebellar ataxia associated with low anti-GAD antibody titers.
resultsThe patient developed progressive cerebellar ataxia over six years. Brain magnetic resonance imaging demonstrated cerebellar atrophy, cerebrospinal fluid analysis revealed type 2 oligoclonal bands, and serum anti-GAD antibodies were detected at a low titer (435 IU/mL), consistent with the recently proposed low-titer anti-GAD cerebellar ataxia (LACA) classification. Partial improvement followed intravenous immunoglobulin and corticosteroids, with sustained improvement after rituximab. The systematic review identified 10 studies including 17 previously reported patients, supporting the diagnostic relevance of low anti-GAD antibody titers in the appropriate clinical context.
conclusionsLow anti-GAD antibody titers do not exclude autoimmune cerebellar ataxia. Diagnosis should integrate clinical presentation, neuroimaging, cerebrospinal fluid findings, and therapeutic response rather than rely solely on serum antibody levels, facilitating earlier diagnosis and timely immunotherapy.
Indexed as
Identifiers
42631769What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.